Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): A comparative analysis

Leukemia

Volumn 27, Issue 5, 2013, Pages 1072-1079

  Kuendgen, A ^a   Lauseker, M ^b   List, A F ^c   Fenaux, P ^d   Giagounidis, A A ^e   Brandenburg, N A ^f   Backstrom, J ^f   Glasmacher, A ^f   Hasford, J ^e   Germing, U ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITÉ PARIS 13   (France)

^e MARIEN HOSPITAL DÜSSELDORF   (Germany)

^f CELGENE CORPORATION   (United States)

Author keywords

acute myeloid leukemia progression; del(5q); lenalidomide; Myelodysplastic syndromes; survival

Indexed keywords

LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CHROMOSOME 5Q; CHROMOSOME DELETION; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DISEASE PROGRESSION; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; THALIDOMIDE;

EID: 84877604495     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.369     Document Type: Article

References (26)

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
2. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q syndrome. Hematology 2004; 9: 271-277.
3. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008; 87: 515-526.
4. Schanz J, Tüchler H, SoléF, Mallo M, Lunõ E, Cervera J et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820-829.
5. Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P et al. Survival, prognostic factors, and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012; 26: 1286-1292.
6. Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Lunõ E et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2011; 25: 110-120.
7. Kulasekararaj AG, Smith AE, Mian SA, Krishnamurthy P, Mohamedali AM, Lea NC et al. TP53 mutations are restricted predominantly to 5q syndrome and myelodysplastic syndrome patients with complex cytogenetics, and correlate with adverse prognosis. Blood 2011; 118: (abstract 792).
8. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
9. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765-3776.
10. Adès L, Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica 2012; 97: 213-218.
11. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
12. Arber DA, Brunning RD, Orazi RD, Bain BJ. Acute myeloid leukaemia with myelodysplasia- related changes. In: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008, 124-126.
13. Allison PD. Survival analysis using the SAS system: A practical guide. SAS Institute: Cary, NC, 1995.
14. Allignol A, Schumacher M, Beyersmann J. Empirical transition matrix of multistate models: the etm package. J Stat Softw 2011; 38: 1-14.
15. Meister R, Schaefer C. Statistical methods for estimating the probability of spontaneous abortion in observational studies-Analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol 2008; 26: 31-35.
16. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-526.
17. Hasserjian RP, Le Beau MM, List AF, Bennett JM, Thiele J. Myelodysplastic syndrome with isolated del(5q). In: Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008, 102.
18. Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström- Lindberg E et al. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol 2010; 89: 365-374.
19. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
20. Howards PP, Hertz-Picciotto I, Poole C. Conditions for bias from differential left truncation. Am J Epidemiol 2007; 165: 444-452.
21. Keiding N, Bayer T, Watt-Boolsen S. Confirmatory analysis of survival data using left truncation of the life times of primary survivors. Stat Med 1987; 6: 939-944.
22. Tsai W-Y, Jewell NP, Wang M-C. A note on the product-limit estimator under right censoring and left truncation. Biometrika 1987; 74: 883-886.
23. Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26: 3607-3613.
24. List AF, Giagounidis A, Backstrom JT, Fu T, Fenaux P. Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with Low-/Int-1-risk myelodysplastic syndromes (MDS) and del5q. J Clin Oncol 2011; 29(15 Suppl): (abstract 6522).
25. Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29: 1971-1979.
26. Jädersten M, Saft L, Pellagatti A, Göhring G, Wainscoat JS, Boultwood J et al. Clonal heterogeneity in the 5q syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009; 94: 1762-1766.